Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum – July 23, 2026
Key Takeaways Roche delivered 6% constant-currency sales growth in H1 2026, driven by Pharmaceuticals and Diagnostics. RHHBY’s growth…
Zacks Industry Outlook Highlights Mitsubishi UFJ Financial, UBS and KB Financial – August 11, 2026
For Immediate Release Chicago, IL – August 11, 2026 – Today, Zacks Equity Research discusses Mitsubishi UFJ Financial…
Roche Holding Ltd RHHBY Stock Forecast & Price Target
Healthcare Argus Jul 28, 2026 Financial Services,Energy,Technology,Real Estate,Healthcare Argus Jul 28, 2026 Healthcare Argus Apr 06, 2026 Market…
ROCHE HOLDING AG I (RHO.F) H1 FY2026 earnings call transcript
Good morning and good afternoon, everyone. I am very much excited to share our half year 2026 results…
Buy 2 SS&C ALPS Mutual Funds for Risk-Adjusted Returns – August 7, 2026
SS&C ALPS Advisors is a U.S.-based asset management company offering a broad range of mutual funds that fall…
Chubb’s Solid Growth Comes With a Premium Valuation – Hold or Buy? – August 3, 2026
Key Takeaways Chubb benefits from broad premium growth across commercial, personal, agriculture and life businesses. Strategic acquisitions and…
Top Stock Reports for Micron Technology, Roche & UnitedHealth – January 7, 2026
Wednesday, January 7, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today’s…
UBS Group Q2 Earnings & Revenues Increase Y/Y Despite Higher Expenses – July 29, 2026
Key Takeaways UBS reported Q2 net profit attributable to shareholders of $2.80 billion, up from $2.39 billion a…
The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS – July 28, 2026
For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in…
This NVDA Partner’s Stock Jumps 7% — Why UBS Sees 38% Upside For Amkor Technology
UBS said Amkor’s expanded $1.5-billion partnership with Nvidia strengthens its position in packaging next-generation AI chips and could…
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well – July 21, 2026
Key Takeaways Novartis beat Q2 earnings and revenue estimates as priority brands helped offset generic competition.NVS reaffirmed 2026…
Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise? – July 17, 2026
Key Takeaways NVS secured full FDA approval for Fabhalta to slow kidney function decline in adults with primary…